Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

NCT02070744 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: VX-661
DRUG: Ivacaftor
DRUG: Placebo matched to VX-661
DRUG: Placebo matched to Ivacaftor

Sponsor

Vertex Pharmaceuticals Incorporated